Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy treatment for major depressive disorder (MDD) in adults who do not respond to ...

Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for Spravato (esketamine) as a monotherapy for adults living with ...

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

Earlier this month, NICE reiterated its position that Spravato should not be used for TRD, after an appeal of earlier rejections by J&J, with a final decision due in mid-December. In the ESCAPE ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants or cannot tolerate them. For too long, health care providers have had few ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder who have not responded to at least two oral antidepressants. This approval ...

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy treatment for major depressive disorder (MDD) in adults who do not ...